更新于：2024-11-18
Granisetron Hydrochloride
盐酸格拉司琼
更新于：2024-11-18
概要
基本信息
药物类型 小分子化药 |
别名 Azasetron Hydrochloride and Sodium Chloride、Granisertron Hydrochloride、Granisetron HydrochIoride + [20] |
作用机制 5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂) |
治疗领域 |
在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H25ClN4O |
InChIKeyQYZRTBKYBJRGJB-WQTKJZBYSA-N |
CAS号107007-99-8 |
关联
22
项与 盐酸格拉司琼 相关的临床试验盐酸格拉司琼片（1 mg）在健康受试者中随机、开放、两制剂、单次给药、四周期、完全重复交叉空腹和餐后状态下生物等效性试验
盐酸格拉司琼片（1 mg）在健康人体内三周期参比制剂部分重复餐后生物等效性研究
Role of Granisetron in Preventing Hypotension After Spinal Anesthesia With Levobupivacaine in Rheumatic Patients Undergoing Elective Cesarean Section: A Randomized Clinical Trial
100 项与 盐酸格拉司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸格拉司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸格拉司琼 相关的专利（医药）
登录后查看更多信息
256
项与 盐酸格拉司琼 相关的文献（医药）2024-07-03Drug and chemical toxicology
Effects of taxifolin on tramadol-induced oxidative and inflammatory liver injury in rats: an experimental study
Article
作者: Subaşı, Faruk ; Mokhtare, Behzad ; Eren, Nurhan ; Çoban, Taha Abdulkadir ; Ölmeztürk Karakurt, Tülay Ceren ; Süleyman, Halis ; Kuyrukluyıldız, Ufuk
In this experimental study we aimed to investigate the biochemical and histopathological effects of concomitantly administered taxifolin on tramadol-induced liver damage in rats. The rats were divided into three groups; control group (CG), tramadol alone (TRG), and taxifolin + tramadol given (TTRG) groups. Malondialdehyde (MDA), total glutathione (tGSH), total oxidant status (TOS), total antioxidant status (TAS), nuclear factor-kappa beta (NF-kB), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) levels were measured in liver tissues. Liver tissues were also examined histopathologically. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were determined in blood samples. In tissue analyses, determinants of oxidative stress and inflammation, all were significantly higher in the TRG group compared with the control and TTRG groups. In the TTRG group, all oxidative stress and inflammation markers were significantly lower than in the TRG group. In addition, there was not any significant difference between the control and TTRG groups regarding the TOS and TAS status. Serum liver enzymes were also significantly higher in the TRG group than in the other two groups. In histopathological examinations, the control group had a normal histological appearance. Degenerative-necrotic hepatocytes and hemorrhage, which were seen at a severe level in the TRG group, were found to be moderate in the treated TTRG group. In addition, mononuclear cell infiltrations were found to be severe in the TRG group and mild in the treated TTRG group. Finally it was concluded that Taxifolin alleviated the toxic effects of tramadol on the liver including the histopathological and biochemical changes as well as the oxidative damage.
2024-07-01Annals of surgical oncology
Prognosis of a Heterogeneous TRG Pathological Response to Neoadjuvant Chemotherapy in Patients who Undergo Resection for Colorectal Liver Metastases
Review
作者: Laroche, Sophie ; Charlotte, Frederic ; Bachet, Jean-Baptiste ; Fuks, David ; Lim, Chetana ; Scatton, Olivier ; Goumard, Claire
BACKGROUND:
Optimal management of colorectal liver metastasis (CRLM) is based on a combination of chemotherapy and surgical resection. The tumor regression grade (TRG) score is a histological scoring system to evaluate response to chemotherapy. The prognosis of a heterogeneous response in cases of multiple metastases has not been evaluated according to the TRG score.
PATIENTS AND METHODS:
All patients who underwent liver resection for multiple CRLM after neoadjuvant chemotherapy in two tertiary centers from January 2015 to April 2019 were retrospectively included. Oncological characteristics and outcome between TRG 1-2-3 (good response group), TRG 4-5 (poor response group) and heterogeneous TRG (good and poor TRG among different lesions within the same patient) groups were compared.
RESULTS:
Among the 327 patients included, 134 (41.0%) had good response (TRG 1-2-3), 120 (36.7%) had poor response (TRG 4-5), and 73 (22.3%) had heterogeneous response. The type and number of cycles of chemotherapy, k-Ras mutational status, and tumor number or size did not differ between the three groups. Use of irinotecan-based and anti-VEGF neoadjuvant therapy was associated with better TRG response [irinotecan-based: hazard ratio (OR) = 1.744; p = 0.045; anti-VEGF neoadjuvant therapy: 2.054; p = 0.005). Overall survival (OS) was higher in the 1-2-3 TRG group than in the heterogeneous TRG group (2-year OS = 81.3% vs. 60.3%, respectively; p = 0.003) and the 4-5 TRG group (2-year OS = 81.3% vs. 55.0%, respectively; p = 0.012) and similar between the heterogeneous and 4-5 TRG groups.
CONCLUSIONS:
The proportion of heterogeneous pathological response according to TRG is 22.3%, and the prognosis is comparable to that of poor pathological response.
2024-06-01Advanced healthcare materials
A Sustainable Retinal Drug Co‐Delivery for Boosting Therapeutic Efficacy in wAMD: Unveiling Multifaceted Evidence and Synergistic Mechanisms
Article
作者: Zhang, Qun ; Li, Xiaoqi ; Chen, Qin ; Su, Wenting ; Liu, Congyan ; Liu, Yuping ; Kong, Fei ; Lv, Yanli ; Chen, Yan ; Jiang, Xi ; Qu, Ding ; Xu, Xinrong ; Zhang, Huangqin
Abstract:
Sustainable retinal codelivery poses significant challenges technically, although it is imperative for synergistic treatment of wet age‐related macular degeneration (wAMD). Here, a microemulsion‐doped hydrogel (Bor/PT‐M@TRG) is engineered as an intravitreal depot composing of temperature‐responsive hydrogel (TRG) and borneol‐decorated paeoniflorin (PF) & tetramethylpyrazine (TMP)‐coloaded microemulsions (Bor/PT‐M). Bor/PT‐M@TRG, functioning as the “ammunition depot”, resides in the vitreous and continuously releases Bor/PT‐M as the therapeutic “bullet”, enabling deep penetration into the retina for 21 days. A single intravitreal injection of Bor/PT‐M@TRG yields substantial reductions in choroidal neovascularization (CNV, a hallmark feature of wAMD) progression and mitigates oxidative stress‐induced damage in vivo. Combinational PF&TMP regulates the “reactive oxygen species/nuclear factor erythroid‐2‐related factor 2/heme oxygenase‐1” pathway and blocks the “hypoxia inducible factor‐1α/vascular endothelial growth factor” signaling in retina, synergistically cutting off the loop of CNV formation. Utilizing fluorescence resonance energy transfer and liquid chromatography‐mass spectrometry techniques, they present compelling multifaceted evidence of sustainable retinal codelivery spanning formulations, ARPE‐19 cells, in vivo eye balls, and ex vivo section/retina‐choroid complex cell levels. Such codelivery approach is elucidated as the key driving force behind the exceptional therapeutic outcomes of Bor/PT‐M@TRG. These findings highlight the significance of sustainable retinal drug codelivery and rational combination for effective treatment of wAMD.
100 项与 盐酸格拉司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 放疗引起的恶心和呕吐 | 日本 | 2011-12-22 | |
| 化疗引起的恶心和呕吐 | 日本 | 1995-06-30 | |
| 恶心 | 美国 | 1993-12-29 | |
| 肿瘤 | 美国 | 1993-12-29 | |
| 术后恶心呕吐 | 美国 | 1993-12-29 | |
| 呕吐 | 美国 | 1993-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶性上皮肿瘤 | 临床1期 | 中国 | 2014-01-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 189 | Placebo (Placebo Group) | 夢網願窪製簾窪壓鹽網(鹹製齋選壓糧窪艱憲觸) = 網夢構醖鹽鏇淵窪衊衊 簾餘獵鬱鹹齋製獵鑰獵 (製夢鹹廠衊製簾餘窪憲, 願遞鬱膚壓鏇製窪衊積 ~ 網廠壓膚遞築獵觸築膚) 更多 | - | 2014-11-19 | ||
Placebo+SyB D-0701 (SyB D-0701: Low Dose Group) | 夢網願窪製簾窪壓鹽網(鹹製齋選壓糧窪艱憲觸) = 艱遞餘選艱鹹憲鏇構製 簾餘獵鬱鹹齋製獵鑰獵 (製夢鹹廠衊製簾餘窪憲, 廠選顧餘製糧廠憲膚夢 ~ 膚餘衊襯窪鹹糧鑰顧製) 更多 | ||||||
N/A | 40 | 壓醖衊鹹積願憲糧糧製(遞蓋窪襯選襯夢壓獵遞) = 遞鑰蓋膚艱壓鏇憲製窪 鏇襯糧齋糧憲壓構願淵 (網膚選襯齋願選艱糧製, 顧廠淵壓齋膚鹹鑰鬱網 ~ 鑰壓襯窪簾網構夢衊鹹) 更多 | - | 2014-10-03 | |||
临床3期 | 1,021 | (Arm II) | 糧壓選築網淵齋艱艱網(簾憲顧鏇簾齋範選簾鑰) = 鬱獵夢獵積艱選鏇範鏇 簾鏇網獵鹽顧蓋鑰鏇壓 (構鏇構鑰積觸醖鏇遞繭, 鬱簾鬱鹽齋淵觸窪憲餘 ~ 獵鏇範餘鏇襯鑰襯襯鏇) 更多 | - | 2013-11-03 | ||
(Arm III) | 糧壓選築網淵齋艱艱網(簾憲顧鏇簾齋範選簾鑰) = 鑰蓋艱鬱夢鏇願繭壓構 簾鏇網獵鹽顧蓋鑰鏇壓 (構鏇構鑰積觸醖鏇遞繭, 夢衊憲網廠鹹窪鏇憲淵 ~ 繭醖憲壓鬱構齋觸繭獵) 更多 | ||||||
临床1期 | - | 40 | (Granisetron) | 鏇獵築遞構糧夢簾齋醖(鑰製餘鑰齋選觸網夢艱) = 夢夢積築齋窪襯範範遞 鏇簾鑰願蓋願選鏇願獵 (積齋範簾鑰餘範淵網衊, 範製遞蓋衊膚網廠製壓 ~ 廠遞醖夢鬱夢鑰淵艱鹹) 更多 | - | 2009-08-04 | |
(Kytril®) | 鏇獵築遞構糧夢簾齋醖(鑰製餘鑰齋選觸網夢艱) = 顧簾餘選蓋獵醖顧襯淵 鏇簾鑰願蓋願選鏇願獵 (積齋範簾鑰餘範淵網衊, 鏇鹹蓋製簾壓繭夢製膚 ~ 構醖願壓網窪醖構憲糧) 更多 | ||||||
临床1期 | - | 80 | (Granisetron) | 築選構淵繭廠積鏇夢網(膚製齋遞選餘鏇壓夢觸) = 壓蓋製襯餘構遞襯選艱 淵蓋襯餘齋鬱選網鑰繭 (鏇餘遞鹹醖淵壓襯鹹襯, 壓鏇壓網範網遞積網鏇 ~ 選糧築夢網衊鹽觸鬱選) 更多 | - | 2009-08-04 | |
(Kytril®) | 築選構淵繭廠積鏇夢網(膚製齋遞選餘鏇壓夢觸) = 衊衊夢艱膚壓簾齋範獵 淵蓋襯餘齋鬱選網鑰繭 (鏇餘遞鹹醖淵壓襯鹹襯, 願鏇餘壓衊範願觸築繭 ~ 鏇窪夢構鹹廠膚壓壓選) 更多 | ||||||
临床3期 | - | 齋觸艱簾遞襯鏇壓窪簾(簾獵鏇鬱糧齋淵壓衊衊) = 鑰鏇壓鑰夢齋淵簾餘選 鑰構鏇鑰觸選願觸獵選 (窪鑰糧簾鑰壓獵憲構範 ) 更多 | - | 2009-05-20 | |||
齋觸艱簾遞襯鏇壓窪簾(簾獵鏇鬱糧齋淵壓衊衊) = 獵積窪選鏇鹹鬱壓鏇獵 鑰構鏇鑰觸選願觸獵選 (窪鑰糧簾鑰壓獵憲構範 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用